Literature DB >> 9494064

Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.

W Kromer1, U Krüger, R Huber, M Hartmann, V W Steinijans.   

Abstract

Gastric proton pump inhibitors (PPIs) are substituted benzimidazole prodrugs that require an acid-induced activation. Its rate depends on the reactivity of the molecule relative to the environmental pH and determines the drug's tissue selectivity. Factors affecting the exposure of moderately acidic tissues to the activated PPI are the area under the serum concentration-time curve (AUC), serum protein binding, the partition coefficient logP and the serum elimination half-life relative to the chemical activation half-life at a critical tissue pH of about 5. These parameters have therefore been determined in a comparative fashion in the present study. The data shows that pantoprazole is less likely to undergo unwanted activation at moderately acidic targets as opposed to the parietal cell, compared to omeprazole. Actually, although 40 mg pantoprazole (steady state) gave a slightly higher serum AUC of the total parent compound than 40 mg omeprazole (10.5 vs. 7.1 micromol x h x l[-1]), a higher serum protein binding of pantoprazole versus omeprazole (98 vs. 96%) reversed the AUC values for the free drug in favor of a lower value for pantoprazole (0.19 vs. 0.28 micromol x h x l[-1]). It is the free parent compound that equilibrates across cell membranes to be activated in acidic tissue compartments. At pH 5.1, the activation half-life of pantoprazole was 4.7 versus 1.4 h for omeprazole, the latter being in the order of the common serum elimination half-life determined in an intraindividual comparison (1.24 vs. 1.25 h). Thus, pantoprazole is eliminated faster from blood than it is activated at a pH of about 5, while omeprazole is as quickly activated at this pH as it is eliminated from blood. Biological in vitro experiments confirmed that pantoprazole displays a lower liability to interfere with unwanted biological targets. This has been demonstrated in vitro for inhibition of both renal Na+/K+-ATPase, lysosomal acidification and the production of reactive oxygen species by neutrophils.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9494064     DOI: 10.1159/000028183

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  15 in total

Review 1.  Gastric H,K-ATPase as a drug target.

Authors:  Jai Moo Shin; George Sachs
Journal:  Dig Dis Sci       Date:  2006-04-28       Impact factor: 3.199

Review 2.  Antiplatelet drug interactions with proton pump inhibitors.

Authors:  Stuart A Scott; Aniwaa Owusu Obeng; Jean-Sébastien Hulot
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-11-09       Impact factor: 4.481

Review 3.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades.

Authors:  Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

5.  Helicobacter pylori reduces intracellular glutathione in gastric epithelial cells.

Authors:  W Beil; B Obst; K F Sewing; S Wagner
Journal:  Dig Dis Sci       Date:  2000-09       Impact factor: 3.199

Review 6.  Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

Authors:  Malcolm Robinson; John Horn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Pantoprazole: a proton pump inhibitor.

Authors:  Luis Moreira Dias
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 8.  Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.

Authors:  Bjarni Thjodleifsson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 9.  The use of proton pump inhibitors in children: a comprehensive review.

Authors:  Troy E Gibbons; Benjamin D Gold
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers.

Authors:  Wolfgang Schillinger; Nina Hörnes; Nils Teucher; Samuel Sossalla; Daniel Sehrt; Klaus Jung; Mark Hünlich; Bernhard Unsöld; Bianca Geiling; Giuliano Ramadori; Reinhard Hilgers; Harald Schwörer; Gerd Hasenfuss
Journal:  Clin Res Cardiol       Date:  2009-03-20       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.